PF-Atlas › Clinical Trials › NCT07719023
A Phase 3 Study of Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary Fibrosis
AK3280 · Phase 3
Registry ID
NCT07719023
Phase
Phase 3
Status
Not yet recruiting
Drug / intervention
AK3280
Sponsor
Shanghai Ark Biopharmaceutical Co., Ltd.
Start
2026-08-31
Enrollment
263
Locations
1
About this trial
This is a phase 3 clinical study conducted in China. The primary objective is to compare the efficacy and safety of AK3280 400 mg versus placebo and active control (pirfenidone) in IPF patients.
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT07719023 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.